Amersham buys Sorin Diagnostics

Article

Radiopharmaceutical developer Amersham International in Decemberbought the radiopharmaceutical business and associated assets of Sorin Diagnosticsof Italy from parent Sorin Biomedica. Amersham, of Buckinghamshire,U.K., paid an initial consideration of

Radiopharmaceutical developer Amersham International in Decemberbought the radiopharmaceutical business and associated assets of Sorin Diagnosticsof Italy from parent Sorin Biomedica. Amersham, of Buckinghamshire,U.K., paid an initial consideration of Lit 22 billion ($13.9 million)in two installments, to be followed by payments ranging from Lit5 billion ($3.1 million) to Lit 28 billion ($17.6 million), dependingon sales results.

Amersham believes that the acquisition will boost its operationsin southern Europe. The company will combine its radiopharmaceuticalbusiness in Italy with Sorin's to form a new division known asAmersham Sorin Radiofarmaci. Sorin posted 1995 annual sales ofLit 33.7 billion ($21.2 million), with pretax profit of Lit 4.2billion ($2.6 million).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.